(Reuters) – The longest-running trial of stem cells derived from a human embryo found that the cells caused patients none of the problems scientists feared, such as forming tumors, and reversed partial blindness in about half the eyes receiving transplants, researchers reported on Tuesday. Continue Reading »
Articles Tagged: Stem Cells
NEWARK, Calif., Oct. 7, 2014 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell based therapies for the treatment of disorders of the central nervous system, announced today that it has initiated its Pathway® Study, a Phase II proof of concept clinical trial using its proprietary HuCNS-SC® platform of human neural stem cells for the treatment of cervical spinal cord injury (SCI). Approximately 1.3 million people in the United States report being paralyzed due to an SCI, and there currently are no effective treatments available. Approximately 56% of the spinal cord injuries occur in the cervical region. Overall, approximately 13% of SCI patients have no mobility and 35% have limited mobility after the traumatic injury. Continue Reading »
Stem cells hold great promise as a means of repairing cells in conditions such as multiple sclerosis, stroke or injuries of the spinal cord because they have the ability to develop into almost any cell type. Now, new research shows that stem cell therapy can also work through a mechanism other than cell replacement.
In a study published today in Molecular Cell, a team of researchers led by the University of Cambridge has shown that stem cells “communicate” with cells by transferring molecules via fluid filled bags called vesicles, helping other cells to modify the damaging immune response around them. Continue Reading »
It’s one of the latest efforts to remake tissue in the lab. The discovery could lead to more research into human development and disease progression.
Using stem cells, scientists have recreated the cells that form an embryo’s spinal cord, muscle and bone tissue. This will help researchers further study embryonic development and possibly, one day, disease progression.
Neuro-mesodermal progenitors (NMPs) — the particular cells that form the spinal cord, muscle and skeleton — begin their transformation once given the go-ahead by certain chemical signals in the body. Continue Reading »
The specialized cells that go on to form the spinal cord, muscle and bone tissue in a growing embryo have been produced in the laboratory using stem cells for the first time.
The spinal cord, muscle and skeleton cells are all formed from cells called neuro-mesodermal progenitors (NMPs). A process of carefully timed chemical signals in the growing embryo instructs NMPs to turn into the different cells required for these body parts. Continue Reading »
Quadriplegic Perry Cross on why he travels to India as a ‘stem cell tourist’ to find a cure for paralysis
PERRY Cross was just 19 when he suffered a devastating neck injury that should have killed him.
Doctors told his family he had months to live, and if he survived beyond that the best he could hope for as a quadriplegic was just 10 years.
Now almost 20 years later, Mr Cross is still cheating death after a rugby accident that left him unable to walk, talk, eat, move his head or even breathe without the help of a respirator. Continue Reading »
Robert Waddell says he’s glad the stem cells that healed him came from “a guy who was 50 years old” and not a human embryo.
As a Catholic, Waddell opposes the destruction of embryos and didn’t want to rely on embryonic stem cells to cure his kidney disease. But he avoided this moral dilemma by getting bone marrow stem cells from a friend who donated a kidney as part of a University of Louisville study.
“It has nothing to do with embryonic stem cells,” said Waddell, a 47-year-old father of four. “That made it a lot easier.” Continue Reading »
(CNN) — Here’s a look at what you need to know about stem cells.
Scientists believe that stem cell research can be used to treat medical conditions including Parkinson’s Disease, spinal cord injury, stroke, burns, heart disease, diabetes, osteoarthritis, and rheumatoid arthritis. Continue Reading »
While human embryonic stem cells (hESCs) were originally created in 1998, it wasn’t until 2009 — over a decade later — that they were approved by the FDA for use in a clinical trial in people. It was a long wait, but the trial was quite the promising one. The clinical trial, undertaken by the Geron Corporation, was for using hESCs to treat patients with spinal cord injuries and paralysis.
Very unfortunately, the trial became stalled in late 2011, mostly due to financial concerns (but it did undoubtedly help pave the way for other hESC-based clinical trials to get FDA approval starting in 2010). Continue Reading »
Neuralstem, announced that the Institutional Review Board of the University of California, San Diego, School of Medicine has approved the phase I safety trial to treat chronic spinal cord injury (cSCI) with its NSI-566 stem cells. The NSI-566/cSCI phase I trial will enroll patients with thoracic spinal cord injuries (T2-T12) who have an American Spinal Injury Association (AIS) A level of impairment, between one and two years after injury. AIS A impairment, which is complete paralysis, refers to a patient with no motor or sensory function in the relevant segments at and below the injury. Continue Reading »